There are currently 378 clinical trials in Grand Rapids, Michigan looking for participants to engage in research studies. Trials are conducted at various facilities, including Spectrum Health at Butterworth Campus, Helen DeVos Children's Hospital at Spectrum Health, CCOP - Grand Rapids and Mercy Health Saint Mary's. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Safety, Tolerability, Pharmacokinetics, Radiation Dosimetry, and PET Imaging Properties of 89Zr-labeled hNd2 (NMK89) in Patients With Pancreatic Cancer
NCT06129422
Recruiting
This trial will be a non-randomized, Phase I trial to evaluate safety, tolerability, biodistribution, radiation dosimetry, pharmacokinetics and PET imaging properties following an infusion of 37 MBq (1 mCi) of 89Zr-labeled hNd2* (NMK89) in patients with pancreatic cancer that are positive for MUC5AC. Image acquisition is conducted using a PET/CT machine. * hNd2: Recombinant humanized Nd2 (anti-human MUC5AC monoclonal antibody)
Gender:
All
Ages:
18 years and above
Trial Updated:
03/29/2024
Locations: BAMF Health, Grand Rapids, Michigan
Conditions: Pancreatic Cancer
Register for Updates
A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid Tumors
NCT05109975
Recruiting
This study has two parts: Part 1 and Part 2. The purpose of this study in Part 1, Dose Escalation Part is to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of Debio 0123 as monotherapy with repeated dosing in adults with advanced solid tumors that recurred or progressed after prior therapy and/or for whom no standard therapy of proven benefit is available. The purpose in Part 2, Expansion Part of this study, is to characterize the safety and tolerability o... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/28/2024
Locations: South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids, Michigan
Conditions: Advanced Solid Tumors
Register for Updates
Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients Who Present With Symptomatic Heart Failure With Reduced Ejection Fraction (HFrEF): The CORCINCH-HF Study
NCT04331769
Recruiting
Prospective, randomized, open-label, international, multi-center clinical study to evaluate the safety and efficacy of the AccuCinch Ventricular Restoration System in patients with heart failure and reduced ejection fraction (HFrEF).
Gender:
All
Ages:
18 years and above
Trial Updated:
03/27/2024
Locations: Spectrum Health, Grand Rapids, Michigan
Conditions: Heart Failure With Reduced Ejection Fraction (HFrEF), Dilated Cardiomyopathy
Register for Updates
Fenofibrate for Prevention of DR Worsening
NCT04661358
Recruiting
This randomized trial will evaluate the effect of fenofibrate compared with placebo for prevention of diabetic retinopathy (DR) worsening through 6 years of follow-up in eyes with mild to moderately severe non-proliferative DR (NPDR) and no CI-DME at baseline. In addition to evaluating efficacy, this study aims to evaluate the feasibility of a model for ophthalmologists to prescribe or collaborate with a primary care provider such as an internist/endocrinologist to prescribe and monitor the dru... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
03/25/2024
Locations: Foundation for Vision Research and Retina Specialists of Michigan, P.C., Grand Rapids, Michigan +1 locations
Conditions: Diabetic Retinopathy
Register for Updates
Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.
NCT03242642
Recruiting
Multi-center, global, prospective, non-randomized, interventional, pre-market trial. All subjects enrolled with receive the study device.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/25/2024
Locations: Spectrum Health Hospital, Grand Rapids, Michigan
Conditions: Mitral Valve Regurgitation
Register for Updates
Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML
NCT05275439
Recruiting
SL03-Old Hundred(OHD)-104 is designed as a Phase 1a/1b open label, trial to evaluate the safety, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary efficacy of SL-172154 monotherapy as well as in combination with azacitidine or in combination with Azacitidine and Venetoclax.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/21/2024
Locations: START Midwest, Grand Rapids, Michigan
Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes
Register for Updates
Pediatric Obesity Weight Evaluation Registry (POWER) Study
NCT02121132
Recruiting
The main objective of this study is to establish a national pediatric obesity registry known as POWER (Pediatric Obesity Weight Evaluation Registry). This registry will contain clinical data from individual comprehensive pediatric weight management programs around the United States for overweight and obese youth.
Gender:
All
Ages:
18 years and below
Trial Updated:
03/21/2024
Locations: Helen DeVos Children's Hospital, Grand Rapids, Michigan
Conditions: Overweight, Obesity
Register for Updates
A Phase 1 Study of RO7623066 Alone and in Combination in Patients With Advanced Solid Tumors
NCT05240898
Recruiting
This is a Phase 1 study to assess the safety and clinical activity of RO7623066 alone and in combination in patients with advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/21/2024
Locations: START Midwest, Grand Rapids, Michigan
Conditions: Advanced Solid Tumors
Register for Updates
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
NCT03907046
Recruiting
Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF). Secondary Aim: To determine if apixaban, compared with aspirin, results in better functional outcomes as measured by the modified Rankin Scale.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/20/2024
Locations: Trinity Health Saint Mary's, Grand Rapids, Michigan +1 locations
Conditions: Intracerebral Hemorrhage, Atrial Fibrillation
Register for Updates
Assessment of GORE® SYNECOR Biomaterial in Focused Patient Populations and Long-Term Application
NCT05094089
Recruiting
The SYN 20-01 Study is a non-interventional, prospective, multicenter, multicohort, international, post-market clinical investigation looking into the assessment of GORE® SYNECOR Biomaterial in focused patient populations and in long-term application. Patients with ventral / incisional hernia amenable to hernia mesh repair will be enrolled into two cohorts (US and EU cohort) and followed-up over the period of 60 months.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
03/16/2024
Locations: Corewell Health, Grand Rapids, Michigan
Conditions: Hernia, Ventral, Hernia Incisional, Hernia Incisional Ventral
Register for Updates
I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients
NCT04488081
Recruiting
The goal of this project is to rapidly screen promising agents, in the setting of an adaptive platform trial, for treatment of critically ill COVID-19 patients. In this phase 2 platform design, agents will be identified with a signal suggesting a big impact on reducing mortality and the need for, as well as duration, of mechanical ventilation.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/12/2024
Locations: Corewell Health, Grand Rapids, Michigan
Conditions: COVID-19
Register for Updates
Evaluation of the PrevisEA Device for Predicting Gastrointestinal Impairment
NCT04880473
Recruiting
PrevisEA is a noninvasive, disposable device that uses audio spectral analysis of sounds produced by the gastrointestinal tract to predict gastrointestinal impairment (GII). GII is most commonly associated with postoperative ileus (POI), but could be the result of other causes, such as early postoperative bowel obstruction. GII is defined as failure of successful early oral re-feeding in a subject undergoing major abdominal surgery. For subjects who are allowed to resume a diet during the first... Read More
Gender:
All
Ages:
Between 18 years and 90 years
Trial Updated:
03/11/2024
Locations: Spectrum Health Blodgett Hospital, Grand Rapids, Michigan
Conditions: Gastrointestinal Complication
Register for Updates